Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy

Acta Neurologica Scandinavica

Volumn 110, Issue 2, 2004, Pages 128-135

  Mishina, M ^a,b,c   Ishii, K ^b   Mitani, K ^b   Ohyama, M ^b,c   Yamazaki, M ^b,c   Ishiwata, K ^b   Senda, M ^a,b   Kobayashi, S ^d   Kitamura, S ^c,e   Katayama, Y ^c  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^e NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

Author keywords

Early diagnosis; Glucose metabolism; Positron emission tomography; Progressive supranuclear palsy; Statistical parametric mapping; Unified Parkinson's Disease Rating Scale

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE DERIVATIVE;

AGED; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CLINICAL FEATURE; CONTROLLED STUDY; DETERIORATION; DIAGNOSTIC VALUE; FEMALE; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; RATING SCALE;

ADULT; AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MESENCEPHALON; MIDDLE AGED; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; SUPRANUCLEAR PALSY, PROGRESSIVE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 3843088519     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2004.00293.x     Document Type: Article

References (37)

1. STEELE JC, RICHARDSON JC, OLAZEWSKI J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-59.
2. HUGHES AJ, BEN-SHLOMO Y, DANIEL SE, LEES AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-6.
3. LITVAN I, MANGONE CA, MCKEE A et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60:615-20.
4. NATH U, BEN-SHLOMO Y, THOMSON RG, LEES AJ, BURN DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003;60:910-6.
5. KOMPOLITI K, GOETZ CG, LITVAN I, JELLINGER K, VERNY M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55:1099-102.
6. ROGERS SL, DOODY RS, MOHS RC, FRIEDHO LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-31.
7. MCKEITH I, DEL SER T, SPANO P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.
8. LITVAN I, PHIPPS M, PHARR VL, HALLETT M, GRAFMAN J, SALAZAR A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001;57:467-73.
9. D'Antona R, Baron JC, Samson Y et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985;108:785-99.
10. BLIN J, BARON JC, DUBOIS B et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990;47:747-52.
11. FOSTER NL, GILMAN S, BERENT S, MORIN EM, BROWN MB, KOEPPE RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988;24:399-406.
12. SALMON E, VAN DER LINDEN MV, FRANCK G. Anterior cingulate and motor network metabolic impairment in progressive supranuclear palsy. Neuroimage 1997;5:173-8.
13. GARRAUX G, SALMON E, DEGUELDRE C, LEMAIRE C, LAUREYS S, FRANCK G. Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortico-frontal dementia, and cortical frontal dementia. Neuroimage 1999;10:149-62.
14. FRISTON KJ, ASHBURNER J, FRITH CD, POLINE JB, HEATHER JD, FRACKOWIAK RS. Spatial registration and normalization of images. Hum Brain Mapp 1995;2:165-8.
15. FRISTON IG, HOLMES AP, WORSLEY KJ, POLINE JP, FRITH CD, FRACKOWIAK RS. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189-210.
16. ALBIN RL, MINOSHIMA S, D'AMATO CJ, FREY KA, KUHL DA, SIMA AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-6.
17. BOHNEN NI, MINOSHIMA S, GIORDANI B, FREY KA, KUHL DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999;52:541-6.
18. 18FDG-PET study. Brain 2000;123:340-52.
19. LITVAN I, AGID Y, CALNE D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
20. FAHN S, ELTON RL, COMMITTEE MOUD. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DC, Goldstein M, eds. Recent development in Parkinson's disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987;153-64.
21. IIDA H, MIURA S, KANNO I, MURAKAMI M, TAKAHASHI K, UEMURA K. Design and evaluation of HEADTOME-IV, a wholebody positron emission tomograph. IEEE Trans Nucl Sci 1989;NS-36:1006-10.
22. SANTACRUZ P, UTTL B, LITVAN I, GRAFMAN J. Progressive supranuclear palsy: a survey of the disease course. Neurology 1998;50:1637-47.
23. PETIT-TABOUE MC, LANDEAU B, DESSON JF, DESGRANGES B, BARON JC. Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage 1998;7:176-84.
24. ZUENDORF G, KERROUCHE N, HERHOLZ K, BARON JC. Efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Hum Brain Mapp 2003;18:13-21.
25. SALAT DH, KAYE JA, JANOWSKY JS. Prefrontal gray and white matter volumes in healthy aging and Alzheimer disease. Arch Neurol 1999;56:338-44.
26. TISSERAND DJ, PRUESSNER JC, SANZ ARIGITA EJ et al. Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare volumetric approaches and voxel-based morphometry. Neuroimage 2002;17:657-69.
27. HOF PR, DELACOURTE A, BOURAS C. Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: a quantitative analysis of six cases. Acta Neuropathol (Berl) 1992;84:45-51.
28. BRAAK H, JELLINGER K, BRAAK E, BOHL J. Allocortical neurofibrillary changes in progressive supranuclear palsy. Acta Neuropathol (Berl) 1992;84:478-83.
29. BIGIO EH, BROWN DF, WHITE CL, JR. Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol 1999;58:359-64.
30. LITVAN I, GRIMES DA, LANG AE et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999;246(Suppl. 2):III-5.
31. CORDATO NJ, HALLIDAY GM, HARDING AJ, HELY MA, MORRIS JG. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol 2000;47:718-28.
32. CORDATO NJ, PANTELIS C, HALLIDAY GM et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 2002;125:789-800.
33. MISHINA M, SENDA M, ISHII K, OHYAMA M, KITAMURA S, KATAYAMA Y. Cerebellar activation during ataxic gait in olivopontocerebellar atrophy: a PET study. Acta Neurol Scand 1999;100:369-76.
34. 99mTc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. Neuroimage 2002;17:1193-202.
35. 15 O positron emission tomography perfusion Z score. Neuroradiology 2000;42:787-94.
36. 18F-FDG PET in localization of frontal lobe epilepsy: comparison of visual and SPM analysis. J Nucl Med 2002;43:1167-74.
37. VAN LAERE KJ, WARWICK J, VERSIJPT J et al. Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative, and voxel-based methods. J Nucl Med 2002;43:458-69.